• Savara presented new biomarker results from the double-blind period of the Phase 3 IMPALA-2 trial of inhaled molgramostim in autoimmune pulmonary alveolar proteinosis at the American Thoracic Society International Conference 2026.
• The data linked treatment to better lung function versus placebo, supported by declines in disease-related biomarkers.
• Analyses also showed that larger biomarker declines tracked with larger improvements in pulmonary gas transfer across the study population.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260520792505) on May 20, 2026, and is solely responsible for the information contained therein.